Skip to content
The Nexus
HEALTHJul 23 · 11:10 UTCQUARTZCris Tolomia

Eli Lilly is pushing its next-generation weight loss drug approval filing to early 2027

Eli Lilly is delaying the FDA approval filing for its next-generation triple-hormone weight loss drug from this year to early 2027. The company had previously indicated it could seek approval as early as 2024.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Eli LillyorganizationFDAorganizationtriple-hormone drugtopicweight loss drugtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

Eli Lilly is pushing its next-generation weight loss drug approval filing to early 2027 · The Nexus